$ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Healthcare
Sector
Biotechnology
Industry
Randy Teel
CEO
430
Employees
$10.94
Current Price
$867.80M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $71,431.07 | 6,435 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $71,431.07 | 6,435 | ||
| 1 month | Buys | 1 | 1 | $268,070.00 | 20,000 | 1:2.44 |
| Sells | 5 | 9 | $653,141.13 | 51,235 | ||
| 2 months | Buys | 1 | 1 | $268,070.00 | 20,000 | 1:3.36 |
| Sells | 6 | 14 | $900,809.83 | 72,065 | ||
| 3 months | Buys | 1 | 1 | $268,070.00 | 20,000 | 1:3.36 |
| Sells | 6 | 14 | $900,809.83 | 72,065 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Berkowitz Noah Chief Medical Officer | Sale | 6,435 | $11.10 | $71,431.07 | View Details |
| Mar 6, 2026 | Morrison Briggs Director | Purchase | 20,000 | $13.40 | $268,070.00 | View Details |
| Feb 27, 2026 | Houston John G Director | Sale | 4,688 | $13.24 | $62,069.12 | View Details |
| Feb 27, 2026 | Houston John G Director | Sale | 18,822 | $13.24 | $249,203.28 | View Details |
| Feb 27, 2026 | Houston John G Director | Sale | 11,787 | $13.14 | $154,881.18 | View Details |
| Feb 23, 2026 | Loomis David K Chief Accounting Officer | Sale | 1,108 | $12.16 | $13,473.28 | View Details |
| Feb 23, 2026 | Cacace Angela M Chief Scientific Officer | Sale | 1,038 | $12.16 | $12,622.08 | View Details |
| Feb 23, 2026 | Cacace Angela M Chief Scientific Officer | Sale | 2,571 | $12.16 | $31,263.36 | View Details |
| Feb 23, 2026 | Teel Randy Director | Sale | 1,038 | $12.16 | $12,622.08 | View Details |
| Feb 23, 2026 | Teel Randy Director | Sale | 3,748 | $12.16 | $45,575.68 | View Details |
| Feb 13, 2026 | Teel Randy Director | Sale | 4,403 | $11.89 | $52,351.67 | View Details |
| Feb 13, 2026 | Saik Andrew Chief Financial Officer | Sale | 5,134 | $11.89 | $61,043.26 | View Details |
| Feb 13, 2026 | Cacace Angela M Chief Scientific Officer | Sale | 4,592 | $11.89 | $54,598.88 | View Details |
| Feb 13, 2026 | Berkowitz Noah Chief Medical Officer | Sale | 5,685 | $11.89 | $67,594.65 | View Details |
| Feb 13, 2026 | Loomis David K Chief Accounting Officer | Sale | 1,016 | $11.89 | $12,080.24 | View Details |
4 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.55
ActualN/A
Revenue
Estimated$37.26M
ActualN/A
EPS
Estimated-$0.55
ActualN/A
Revenue
Estimated$37.26M
ActualN/A